EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/02/23
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 08/02/23
EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation SummitGlobeNewsWire • 07/27/23
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023GlobeNewsWire • 07/26/23
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic RetinopathyGlobeNewsWire • 06/05/23
EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug SuccessSeeking Alpha • 05/30/23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus RoyaltiesGlobeNewsWire • 05/18/23
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 05/03/23
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023GlobeNewsWire • 04/26/23
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?Zacks Investment Research • 04/20/23
EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMDGlobeNewsWire • 03/27/23
EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 03/20/23
Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)Zacks Investment Research • 03/09/23
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/02/23
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/02/23
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023GlobeNewsWire • 02/23/23
EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQGlobeNewsWire • 01/23/23
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their OptionsPRNewsWire • 01/22/23